Search the Newsreel

Indocement Tunggal Prakarsa (INTP) Cetak Kinerja Moncer di Semester I-2026

Sakar Healthcare eyes ₹200 crore oncology revenue in FY27

S H Kelkar and Company Limited Just Beat EPS By 228%: Here's What Analysts Think Will Happen Next

Shankara Buildpro Schedules Q1 FY27 Earnings Call for August 7

Kirloskar Brothers targets double-digit revenue growth, bets on domestic and overseas demand

Utkarsh Small Finance Bank Q1 FY27 Results: Net Loss Rs 33 Cr, Re

Sakar Healthcar Standalone June 2026 Net Sales at Rs 72.97 crore, up 38.37% Y-o-Y

Utkarsh Small Finance Bank reports standalone net loss of Rs 33.92 crore in the June 2026 quarter

Hewlett Packard Enterprise (HPE) Joins TangleLab On A Valuation Gap Investors May Still Question

Hewlett Packard Enterprise (HPE) has joined TangleLab, a hybrid quantum and classical supercomputing testbed, following a period of strong share price performance. Despite recent gains, HPE's stock at US$47.90 is still below analyst targets and intrinsic value estimates around US$65.56, suggesting a potential undervaluation …

Price to earnings forward of Kardan Real Estate Enterprise & Development Ltd. – TASE:KARE

Enterprise value to EBIT forward of Peria Karamalai Tea & Produce Co. Ltd. – NSE:PKTEA

Nkarta Inc. (NKTX) Drops 2.79% to $2.09 as Key Support Level Comes into Focus - Wyckoff Distribution

Kirloskar Electric Co accepts resignations of two Vice Presidents

Karooooo Ltd. Actuals & Estimates (NASDAQ:KARO)

This article provides an overview of Karooooo Ltd. (NASDAQ: KARO) stock, including its current price, historical performance, analyst forecasts, and financial data. It details recent earnings, revenue, dividends, market capitalization, and volatility, along with information on how to trade the stock and its technical …

Karbon Capital Partners Corp. Revenue Breakdown – NASDAQ:KBON

This article provides a basic overview of Karbon Capital Partners Corp. (NASDAQ:KBON) on TradingView, focusing on its financial data availability. It indicates that the market was closed with no trades at the time of viewing and lists various features and resources offered by the …

Karooooo CEO and Executive Chairman Isaias Jose Calisto disposes of 50,527 common shares worth $3.25 million

Karooooo's CEO and Executive Chairman, Isaias Jose Calisto, sold 50,527 common shares for approximately $3.25 million on July 29-30. The sales were priced at $64.43 and $63.47 per share, reducing his direct stake to 17,819,482 shares. This transaction was disclosed in a Form 4 …

KIRLOSBROS: Q1FY27 revenue rose 12.9% YoY with strong margins and a robust orderbook supporting growth

Price to earnings forward of Akari Therapeutics Plc – NASDAQ:AKTX

The article focuses on the "Price to earnings forward" metric for Akari Therapeutics Plc (NASDAQ: AKTX). It presents a financial data point for the company, indicating the period and value of this specific financial ratio. The content primarily appears to be a data display …

KARYOPHARM THERAPEUTICS INC : BAIRD CUTS TO NEUTRAL RATING; CUTS TARGET PRICE TO $3 FROM $15

Baird has downgraded Karyopharm Therapeutics Inc (KPTI.O) to a Neutral rating and significantly reduced its target price from $15 to $3. This action indicates a revised outlook on the company's financial prospects by the analyst firm. The article, sourced from Reuters, reports this change …

Q1 Results On August 1: Divi's Labs, Muthoot Finance, CDSL Among Over 30 Firms To Share Earnings

Q1 results: Muthoot Finance, Divi's Labs, Nilkamal, and 30 more on Aug 1

Q1 results today: Divi's Labs, Muthoot Finance, APL Apollo among over 30 companies set to announce Q1 earnings

Karooooo (NASDAQ:KARO) Upgraded by Wall Street Zen to "Buy" Rating

Wall Street Zen has upgraded Karooooo (NASDAQ:KARO) from a "Hold" to a "Buy" rating, aligning with a generally positive analyst outlook and an average price target of $73.50. The company recently reported strong quarterly earnings of $0.59 EPS, beating estimates, and revenue of $96.26 …

Earnings Preview: KRMN to Report Financial Results Post-market on August 06

This article announces that KRMN is scheduled to release its financial results post-market on August 06. It advises investors to monitor the earnings announcement closely for potential impacts on the stock's price, as past performance suggests significant post-earnings volatility.

Akari Therapeutics Plc Revenue Breakdown – NASDAQ:AKTX

This article provides a brief overview of Akari Therapeutics Plc (NASDAQ: AKTX) financials, specifically focusing on its revenue breakdown. It indicates that further detailed financial information, including segments and regional performance, is available through TradingView and its data partners like ICE Data Services and …

Hewlett Packard Enterprise Stock Outlook: Is Wall Street Bullish or Bearish?

Hewlett Packard Enterprise (HPE) has significantly outperformed the market and its industry benchmark over the past year, driven by strong Q2 2026 earnings that exceeded Wall Street forecasts. The company's success is largely attributed to its Cloud and AI revenue, with analysts predicting substantial …

Karyopharm To Stick With Blood Cancers As Xpovio Flops In Endometrial Cancer

Karyopharm is re-focusing its efforts on blood cancers after its drug Xpovio failed in a maintenance trial for endometrial cancer. This strategic shift comes as the company adjusts its research and development priorities following the disappointing trial results. The company will now concentrate on …

HPE Enterprise, Global Sales VP Monica Gille Is Leaving Company, Ready For ‘Next Chapter’

Monica Gille, HPE's Vice President of Sales Enterprise and Global Accounts, is departing the company after 25 years. Gille was responsible for over $7 billion in HPE revenue from the top 500 accounts in North America and played a crucial role in driving enterprise …

Karyopharm’s XPORT-EC-042 study fails to meet primary endpoint

Karyopharm Therapeutics' Phase III XPORT-EC-042 clinical trial for selinexor in advanced or recurrent endometrial cancer failed to meet its primary endpoint of progression-free survival. Despite a trend towards improved PFS in the selinexor arm compared to placebo, statistical significance was not reached, leading to …

Karooooo (NASDAQ:KARO) Hits New 1-Year High - Should You Buy?

Karooooo (NASDAQ:KARO) recently hit a new 52-week high of $66.23, with analyst sentiment remaining positive and an average price target of $73.50. The company exceeded quarterly earnings expectations and increased its annual dividend to $1.50 per share, despite some insider selling. While the stock …

Insider Selling: Karooooo (NASDAQ:KARO) CEO Sells $2,055,123.71 in Stock

Karooooo (NASDAQ:KARO) CEO Isaias Jose Calisto sold $2.06 million worth of stock on July 29, reducing his ownership by 0.18%. This sale was part of several transactions between July 27-30. The company's stock is near its 52-week high, recently exceeded earnings expectations, and increased …

NKTX|Nkarta Inc|Price:2.090|Chg%:-0.060

This article provides a detailed stock analysis of Nkarta Inc (NKTX), highlighting its weak fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes high institutional ownership and recent "Buy" ratings from analysts with a target price of …

Karyopharm's Phase 3 Endometrial Cancer Trial Misses Endpoint; Stock Slides

(RTTNews) - Karyopharm Therapeutics Inc. (KPTI), announced yesterday topline results from its Phase 3 XPORT-EC-042 trial evaluating Selinexor as a maintenance-only therapy in patients with TP53 wild-type advanced or recurrent endometrial cancer. The study did not meet its primary endpoint of progression free survival, …

Karyopharm Therapeutics INC (KPTI) Q4 2023 Earnings Report - Results, Call & Slides

Karyopharm Therapeutics (KPTI) reported its Q4 2023 earnings, missing both EPS and revenue expectations. The company posted an actual EPS of -$5.40 against a consensus of -$4.65, and actual revenue of $33.75M compared to an expected $35.41M, although revenue showed a slight YoY increase …

Karyopharm Therapeutics reports Phase 3 XPORT-EC-042 misses PFS; plans myelofibrosis sNDA

Karyopharm Therapeutics announced that its Phase 3 XPORT-EC-042 trial, testing selinexor maintenance versus placebo, failed to meet its primary progression-free survival (PFS) endpoint. Despite missing this endpoint, the company plans to submit an sNDA in August for accelerated approval of selinexor+ruxolitinib for myelofibrosis, using …

Karyopharm plans selinexor-ruxolitinib combination filing for myelofibrosis accelerated approval

Karyopharm Therapeutics (KPTI) plans to submit a supplemental New Drug Application (sNDA) in August for accelerated approval of its selinexor-ruxolitinib combination therapy for myelofibrosis. The FDA has agreed that spleen volume reduction (SVR35) can serve as a surrogate endpoint for predicting overall survival, based …